前收盘价格 | 5.06 |
收盘价格 | 5.15 |
成交量 | 521,508 |
平均成交量 (3个月) | 1,515,398 |
市值 | 322,775,520 |
价格/销量 (P/S) | 1.60 |
股市价格/股市净资产 (P/B) | 8.83 |
52周波幅 | |
利润日期 | 5 May 2025 - 9 May 2025 |
营业毛利率 | -57.69% |
营业利益率 (TTM) | -48.68% |
稀释每股收益 (EPS TTM) | -1.38 |
季度收入增长率 (YOY) | 10.70% |
总债务/股东权益 (D/E MRQ) | 342.58% |
流动比率 (MRQ) | 1.85 |
营业现金流 (OCF TTM) | -31.00 M |
杠杆自由现金流 (LFCF TTM) | -17.44 M |
资产报酬率 (ROA TTM) | -17.07% |
股东权益报酬率 (ROE TTM) | -148.19% |
市场趋势
短期 | 中期 | ||
行业 | Diagnostics & Research (US) | 混合的 | 混合的 |
Diagnostics & Research (全球的) | 混合的 | 混合的 | |
股票 | Neuronetics, Inc. | 看涨 | 看跌 |
AIStockmoo 评分
分析师共识 | 3.0 |
内部交易活动 | NA |
价格波动 | -3.0 |
技术平均移动指标 | 2.5 |
技术振荡指标 | -0.5 |
平均 | 0.50 |
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options. |
|
部门 | Healthcare |
行业 | Diagnostics & Research |
投资方式 | Small Value |
内部持股比例 | 7.99% |
机构持股比例 | 48.99% |
52周波幅 | ||
目标价格波幅 | ||
高 | 8.00 (Canaccord Genuity, 60.80%) | 购买 |
中 | 7.50 (50.75%) | |
低 | 7.00 (Citizens Capital Markets, 40.70%) | 购买 |
平均值 | 7.50 (50.75%) | |
总计 | 2 购买 | |
平均价格@调整类型 | 5.42 |
公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
---|---|---|---|---|
Canaccord Genuity | 05 Mar 2025 | 8.00 (60.80%) | 购买 | 5.42 |
Citizens Capital Markets | 05 Mar 2025 | 7.00 (40.70%) | 购买 | 5.42 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。
投资组合